What is HC Wainwright’s Estimate for Prothena Q4 Earnings?

Prothena Co. plc (NASDAQ:PRTA) – Research analysts at HC Wainwright issued their Q4 2025 earnings per share (EPS) estimates for Prothena in a report released on Friday, February 21st. HC Wainwright analyst A. Fein expects that the biotechnology company will post earnings of ($0.58) per share for the quarter. HC Wainwright has a “Buy” rating and a $48.00 price objective on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.06). The company had revenue of $2.12 million for the quarter, compared to analyst estimates of $7.53 million. Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%.

PRTA has been the topic of several other reports. Oppenheimer increased their target price on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research report on Friday, February 7th. Chardan Capital restated a “buy” rating and issued a $40.00 target price on shares of Prothena in a report on Friday. Royal Bank of Canada lowered their price objective on shares of Prothena from $24.00 to $20.00 and set a “sector perform” rating on the stock in a research report on Friday. Bank of America decreased their target price on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, December 19th. Finally, StockNews.com raised shares of Prothena from a “sell” rating to a “hold” rating in a report on Monday. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $45.83.

Prothena Stock Performance

NASDAQ:PRTA opened at $15.23 on Monday. The company has a market capitalization of $819.51 million, a price-to-earnings ratio of -6.62 and a beta of 0.08. The stock has a 50-day simple moving average of $14.38 and a 200 day simple moving average of $16.73. Prothena has a one year low of $11.70 and a one year high of $31.03.

Institutional Trading of Prothena

Several large investors have recently bought and sold shares of PRTA. Barclays PLC lifted its position in shares of Prothena by 110.2% in the 3rd quarter. Barclays PLC now owns 95,222 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 49,916 shares during the period. SG Americas Securities LLC boosted its stake in shares of Prothena by 167.0% in the 4th quarter. SG Americas Securities LLC now owns 37,612 shares of the biotechnology company’s stock worth $521,000 after buying an additional 23,525 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Prothena by 1,122.9% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock valued at $8,812,000 after purchasing an additional 483,673 shares during the period. Duncan Williams Asset Management LLC grew its stake in shares of Prothena by 41.9% during the 4th quarter. Duncan Williams Asset Management LLC now owns 69,199 shares of the biotechnology company’s stock worth $958,000 after acquiring an additional 20,450 shares during the period. Finally, Focused Wealth Management Inc purchased a new position in shares of Prothena in the fourth quarter worth about $445,000. 97.08% of the stock is owned by institutional investors and hedge funds.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.